Keros Therapeutics (NASDAQ:KROS) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a research report released on Tuesday, Benzinga reports. The brokerage currently has a $100.00 price target on the stock. Other analysts have also recently issued research reports about the stock. Truist Financial reissued a buy rating and issued a […]
More Stories
StockNews.com Upgrades Thomson Reuters (NYSE:TRI) to “Hold”
StockNews.com upgraded shares of Thomson Reuters (NYSE:TRI – Free Report) (TSE:TRI) from a sell rating to a hold rating in...
Oak Woods Acquisition Co. (NASDAQ:OAKUW) Sees Significant Decline in Short Interest
Oak Woods Acquisition Co. (NASDAQ:OAKUW – Get Free Report) was the recipient of a significant drop in short interest in...
PIMCO Municipal Income Fund III (NYSE:PMX) Short Interest Down 24.4% in October
PIMCO Municipal Income Fund III (NYSE:PMX – Get Free Report) was the recipient of a large decrease in short interest...
Enstar Group Limited (NASDAQ:ESGRO) Short Interest Update
Enstar Group Limited (NASDAQ:ESGRO – Get Free Report) saw a large drop in short interest during the month of October....
Crescent Energy (NYSE:CRGY) Short Interest Down 10.7% in October
Crescent Energy (NYSE:CRGY – Get Free Report) was the target of a significant drop in short interest in October. As...
Short Interest in East West Bancorp, Inc. (NASDAQ:EWBC) Decreases By 10.6%
East West Bancorp, Inc. (NASDAQ:EWBC – Get Free Report) saw a large decline in short interest during the month of...